Sandoz Inc. v. Amgen Inc.
773 F.3d 1274
Fed. Cir.2014Background
- Amgen markets Enbrel®, a biological product, for rheumatoid arthritis; two Hoffman-La Roche patents, the ’182 and ’522, are asserted as covering etanercept; Sandoz began Phase III testing and planned FDA biosimilarity filing but had not filed such an application; Sandoz filed suit for declaratory judgments that the patents are invalid, unenforceable, and noninfringing; the district court dismissed for lack of Article III injury and because BPCIA governs biosimilarity disputes; Sandoz appealed challenging the lack of immediacy/reality to support jurisdiction.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether there is an Article III case or controversy | Sandoz asserts an imminent risk of patent liability once it seeks approval. | Amgen contends no immediate injury or controversy exists absent FDA approval. | No case or controversy present. |
| Whether BPCIA precludes declaratory judgment before FDA biosimilarity application | Sandoz argues FDA process or BPCIA provisions do not compel dismissal. | District court ruling that BPCIA bars suit is appropriate. | Court does not need to address BPCIA applicability given lack of jurisdiction. |
| Role of FDA approval timing and contingencies in justiciability | Contingent future events may still yield a justiciable dispute. | Regulatory contingencies prevent immediacy/reality of infringement risk. | Immediacy and reality not satisfied due to contingent, future-focused activities. |
| Impact of potential product changes on infringement and need for adjudication | Possible product modifications could alter or eliminate disputes. | Uncertainty about future product mapping keeps dispute unresolved. | Contingencies undermine Article III standing. |
Key Cases Cited
- MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (U.S. 2007) (establishes all the circumstances test for declaratory judgments in patent context)
- Medtronic, Inc. v. Mirowski Family Ventures, LLC, 134 S. Ct. 843 (S. Ct. 2014) (highlights ready commercial activity without regulatory hurdles as distinguishing factor)
- Arkema Inc. v. Honeywell Int'l, Inc., 706 F.3d 1351 (Fed. Cir. 2013) (contingency and timing affect justiciability in patent disputes)
- Matthews Int'l Corp. v. Biosafe Eng'g, LLC, 695 F.3d 1322 (Fed. Cir. 2012) (considered immediacy and reality in declaratory-judgment context)
- Cat Tech LLC v. TubeMaster, Inc., 528 F.3d 871 (Fed. Cir. 2008) (examines immediacy/reality in patent declaratory actions)
- Benitec Austl., Ltd. v. Nucleonics, Inc., 495 F.3d 1340 (Fed. Cir. 2007) (supports contingent-future activity undermining immediacy)